Maria Ralli
About
In The Last Decade
Maria Ralli
13 papers receiving 159 citations
Peers
Comparison fields: 5 of 61
- Epidemiology 47
- Pulmonary and Respiratory Medicine 43
- Surgery 26
- Nephrology 25
- Public Health, Environmental and Occupational Health 21
Countries citing papers authored by Maria Ralli
This map shows the geographic impact of Maria Ralli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Ralli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Ralli more than expected).
Fields of papers citing papers by Maria Ralli
This network shows the impact of papers produced by Maria Ralli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Ralli. The network helps show where Maria Ralli may publish in the future.
Co-authorship network of co-authors of Maria Ralli
This figure shows the co-authorship network connecting the top 25 collaborators of Maria Ralli. A scholar is included among the top collaborators of Maria Ralli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Ralli. Maria Ralli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 6 | |
| 2 | 12 | |
| 3 | 1 | |
| 4 | 2 | |
| 5 | 10 | |
| 6 | 23 | |
| 7 | 15 | |
| 8 | 24 | |
| 9 | 21 | |
| 10 | 13 | |
| 11 | Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) | 2 |
| 12 | 20 | |
| 13 | Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. | 13 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.